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Background and aims: Regional differences in the clinical care of Type 1 diabetes (T1D) in Brazil have been
recently described. This study aimed to estimate the costs of T1D from the public health care system’s perspective
across the regions of Brazil and to determine the components that influence these costs.
Methods: This was a retrospective, cross-sectional and nationwide multicenter study conducted between
December 2008 and December 2010 in 28 public clinics in 20 Brazilian cities. The study included 3,180 T1D subjects
receiving healthcare from the National Brazilian Healthcare System (NBHCS) with a follow-up of at least one year.
The direct medical costs were derived from the costs of medications, supplies, examinations, visits to the center,
medical procedures and hospitalizations that occurred during the previous year. Clinical and demographic factors
that determined the differences in the cost across four geographic regions (southeast, south, north/northeast and
mid-west) were investigated.
Results: The per capita mean annual direct medical costs of T1D in US$ were 1,466.36, 1,252.83, 1,148.09 and
1,396.30 in southeast, south, north/northeast and mid-west regions, respectively. The costs of T1D in the southeast
region were higher compared to south (p < 0.001) and north/northeast regions (p = < 0.001), but not to the
mid-west (p = 0.146) region. The frequency of self-monitoring of blood glucose (SMBG) was different across the
regions as well as the daily number of SMBG, use of insulin pumps or basal or prandial insulin analogs. Age,
ethnicity, duration of diabetes, level of care, socioeconomic status and the prevalence of chronic diabetic
complications differed among the regions. In a regression model the determinants of the costs were the presence
of microvascular diabetes-related complications (p < 0.001), higher economic status (p < 0.001), and being from the
southeast region (p < 0.001).
Conclusions: The present data reinforce the regional differences in the costs of T1D and in the socioeconomic
profile and health care provided to the patients with T1D in specialized public centers in Brazil. Both factors
influenced directly the costs of T1D and should be considered for discussing future health policies.
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Figure 1 Distribution of the participating centers across
the country.
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Type 1 diabetes (T1D) is a chronic disease that carries a
large risk of chronic disabling complications that have a
negative impact in the costs of the disease and in the
patient’s quality of life. Moreover, the incidence of T1D
is increasing in many countries, including Brazil [1,2].
Despite the well known benefits of an intensive glucose
control in reducing or postponing the risks of diabetes-
related complications and the costs of the disease, the gly-
cemic control in the majority of patients with T1D in
Brazil does not meet the guidelines recommendations [3].
Brazil is a large country with about 191 · 8 million in-
habitants, according to the last population census con-
ducted by the Brazilian Institute of Geography and
Statistics (IBGE) [4]. It is divided into five major geo-
graphic regions (north, northeast, mid-west, southeast,
and south) and the proportion of people living in urban
areas is of 84% [4]. The regional population densities
present wide disparities. The north region comprises
45 · 2% of the total area of the country and has only 8 ·
1% of the total population. In contrast, the southeast re-
gion accounts for 42% of the total population density
and comprises only 10 · 9% of the total area of the coun-
try [4]. In addition to demographic differences, cultural,
and socioeconomic aspects also differ among regions.
Actually, the functional illiteracy rate in people older
than 14 years was 23 · 1% in the north, 30 · 8% in the
northeast, 15 · 2% in the southeast, 15 · 5% in the south,
and 18 · 5% in the mid-west in 2010 [5].
The direct costs of T1D has been recently estimated in
Brazil [6]. Previous data from our group have shown im-
portant regional differences in the clinical care of T1D
patients in Brazil regarding the achievement of thera-
peutic goals, frequency of screening for chronic diabetes-
related complications, insulin regimens, and frequency of
self-monitoring of blood glucose (SMBG) [7]. The results
found in this study are alarming and suggest that govern-
mental health policy should be directed to each geo-
graphic region, in order to meet their specific demands
and improve the quality of care in the public health care
system overall.
The aim of our study was to estimate the costs of T1D
from the public health care system’s perspective across
the different regions of Brazil and to determine the
regional differences of the components that influence
these costs. We believe these data may provide impor-
tant clues for reassessment of regional health policies in
Brazil.
Research design and methods
Study design
This is a retrospective, cross-sectional and nationwide
multicenter cost-of-illness study conducted between De-
cember 2008 and December 2010 in 28 centers locatedin 20 Brazilian cities in public clinics with secondary and
tertiary care levels (Figure 1). The public healthcare sys-
tem in Brazil is divided in primary, secondary and ter-
tiary care levels according to the characteristics and
infrastructure of the healthcare units. As patients with
T1D usually are treated at secondary or tertiary centers
in our country, primary care centers were not included
in the study. Also, patients attending the private or sup-
plementary health care system (about 24% of the total
Brazilian population) were not included. The detailed
methodology has been described elsewhere [3]. Written
informed consent for the study was obtained from all of
the patients aged 18 years or older or from the parents
or guardians of the patients younger than 18 years. The
study was approved by each local center’s ethics com-
mittee. Only the patients with at least 12 months of
follow-up at the respective center were included. This
inclusion criterion allowed us to quantify the variables
required to determine the costs over the prior year to
the study through an interview.
Economic status was defined according to the Brazilian
Economic Classification Criteria (ABEP) [8], which esti-
mates the purchasing power of urban individuals and
families, thus classifying the population in terms of eco-
nomic strata. These criteria provide scores according to
the ownership of items and education level. Economic sta-
tus were classified as high, middle, low or very low [8].
Assessment of clinical and demographic variables
Information on the diabetic treatment modalities, source
of insulin pumps, medications and supplies for SMBG,
frequency of SMBG, routine diabetes care and other data
not available from medical records (eg. admissions in
Table 1 Clinical and demographic data of the studied
population
Variable
N 3,180
Female gender, n (%) 1,791 (56 · 3)
Age, y 22 ± 11 · 8; 20 (2–66)
Ethnicity, n (%)
Caucasian 1,824 (57 · 4)
Non-Caucasian* 1,356 (42 · 6)
Socioeconomic status**
High 222 (7 · 2)
Medium 710 (22 · 3)
Low 1,052 (33 · 1)
Very low 1,102 (34 · 7)
Level of care, n (%)
Secondary 897 (28 · 2)
Tertiary 2,283 (71 · 8)
Duration of diabetes, y 10 · 3 ± 8 · 03, 8 (1–50)
HbA1c%, mmol/mol 9 · 34 ± 2 · 34, 78.6 ± 25
Presence of microvascular complications† 635 (27 · 4)
Presence of macrovascular complications† 119 (5 · 1)
y = year. The data are presented as number (percentage), mean ± SD and/or
median (Min-Max). *Afro-Brazilians, Mulattos, Asians, Native Indians **Missing
data from 87 participants.
†Excludes the patients without criteria for the diabetic complications screening.
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information provided directly by the patient or his care-
giver. The following information was obtained from
medical records assessed during the interview: the to-
tal number of HbA1c measurements performed in the
prior year, fructosamine levels, fasting, and 2-h post-
prandial glycemia, total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides, uric acid, plasma crea-
tinine, plasma urea, sodium, potassium, liver enzymes
(aspartate [AST] and alanine [ALT] aminotransferase),
C-reactive protein (CRP), thyroid stimulating hormone
(TSH), proteinuria, and albuminuria. The number of tests
performed to screen for diabetes-related complications,
such as electrocardiograms (ECGs), exercise stress tests,
stress echocardiographs, calcium score tomographies,
coronary artery angiographs, and fundoscopies, were
analyzed. The frequencies of medical procedures, such
as vitrectomy, laser therapy, hemodialysis, and hospi-
talizations due to diabetes decompensation or ketoaci-
dosis were also evaluated.
Costs evaluation and distribution of healthcare resources
The direct medical costs were calculated using the costs
of medications (oral drugs and insulin), SMBG supplies,
blood analysis and other examinations, consultations
with physicians, nurses and dietitians, medical proce-
dures, and hospitalizations that occurred during the
prior year. The drugs included in the analysis were those
specific to treating T1D or its related comorbidities
(dyslipidemia, arterial hypertension, obesity), and com-
plications (retinopathy, nephropathy, and neuropathy).
The medication costs were obtained from the Brazilian
Ministry of Health website [9] when the drug was pro-
vided by public institutions or by the average price at
three nationwide pharmaceutical web sites when pri-
vately acquired. When the price varied by region, we cal-
culated the average cost. The costs of examinations and
medical procedures were obtained from the table of pro-
cedures using the 2010–2011 NBHCS prices which de-
termine the reimbursements to government-sponsored
healthcare units. The price of insulin pumps and their
supplies was based on the value paid by the Municipal
Health Bureau of Rio de Janeiro (RJ-SMS) in May 2010.
The costs of SMBG supplies, syringes, and needles were
determined by the April 2011 RJ-SMS or by the mean
values for three nationwide pharmaceutical companies
when privately acquired.
All of the costs were converted into US dollars (at 1
US dollar = 1 · 9315 Reais) using the average of the 3
consecutive years (2008–2010).
Data storage and statistical analysis
The statistical analysis was performed using the Statis-
tical Package for the Social Sciences (SPSS) Version 17.0.Data are presented as mean [95% confidence interval]
for continuous variables and as counts (relative frequen-
cies) for discrete variables.
Comparison of the direct medical costs across the four
regions was performed using non- parametric test Mann–
Whitney for every two regions. The statistically significant
p-values were corrected using the Sidak procedure to con-
trol for type I errors (p < 0 · 01). Data on the north and
northeast regions were evaluated together, so four geo-
graphic regions were compared (southeast, n = 1,310;
south, n = 727; north/northeast, n = 938, and mid-west,
n = 205). A regression analysis was performed to investi-
gate the role of the geographic regions and other inde-
pendent variables (age, ethnicity, duration of diabetes,
economic status, level of attention, and the presence of
microvascular or macrovascular diabetes-related compli-
cations) in influencing the direct medical costs. In this re-
gression analysis the geographic regions were introduced
in the model as dummies variables.
Results
The clinical and demographic characteristics of the stud-
ied populations are presented in Table 1. The per capita
mean [95% IC] direct medical costs of T1D were US$
1,466 · 36 [1,382 · 09-1,550 · 64], US$ 1,252 · 83 [1,168 ·
66-1,337 · 00], US$ 1,148 · 09 [1,048 · 86-1,247 · 32], and
Table 2 Total annual costs (US$) of the studied population across the different geographic regions in Brazil
Southeast (n = 1310) South (n = 727) North/Northeast (n = 938) Mid-West (n = 205)
Direct medical cost (US$)
Total 1,920,936 · 74 910,808 · 38 1,076,906 · 08 286,241 · 19
Per capita 1,466 · 36 1,252 · 83 1,148 · 09 1,396 · 30
[1,382 · 09–1,550 · 64] [1,168 · 66–1,337 · 00] [1,048 · 86–1,247 · 32] [1,268 · 30–1,370 · 00]
1,052 · 10 885 · 54 654 · 86 986 · 42
(778 · 65–1,710 · 46) (698 · 01–1,513 · 22) (429 · 77–1,164 · 17) (631 · 81–1,871 · 78)
Data presented as mean [95% CI] and median (interquartile range). Southeast vs south (p < 0 · 001); southeast vs north/northeast (p < 0 · 001); southeast vs
midwest (p = 0 · 146); midwest vs north/northeast (p = <0 · 001); south vs northeast (p < 0 · 001); south vs midwest (p = 0 · 292).
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north/northeast, and midwest regions, respectively. The
costs of T1D in the southeast region were higher com-
pared to the south (p < 0 · 001), and north/northeast
regions (p < 0 · 001), but not to the mid-west region
(p = 0 · 146). Midwest costs were statistically different
from north/northeast (p < 0 · 001) but not from south
regions (p = 0 · 292). South costs were higher than north/
northeast (p < 0 · 001) (Table 2).
The components of the clinical care of diabetes that
most impacted the direct medical costs were compared
among the regions aiming to find explanations for the
regional differences of these costs (Table 3). As previ-
ously shown, the frequency of SMBG is different across
the regions (p < 0 · 001) as well as the daily number of
SMBG (p < 0 · 001), use of insulin pumps (p = 0 · 009) or
basal or prandial insulin analogs (p < 0 · 001).
The clinical and demographic variables that could have
influenced the costs were compared among the regions
and the results are shown in Table 4. Age (p = 0 · 017), eth-
nicity (p < 0 · 001), duration of diabetes (p < 0 · 001), level
of care (p < 0 · 001), socioeconomic status (p < 0 · 001) and
the prevalence of chronic diabetes-related microvascular
(p < 0 · 001) and macrovascular (p = 0 · 004) complications
differed among the regions but not gender.
In the regression model using the direct medical costs
as the dependent variable and geographic region, age,
ethnicity, duration of diabetes, level of attention, socio-
economic status and the presence of chronic microvascu-
lar or macrovascular diabetes-related complications as the
independent variables we observed that the independentTable 3 Differences in the resources utilization among the ge
Southeast
SMBG (yes), (%) 93 · 9
Daily frequency of SMBG* 3 · 88 [3 · 78–3 · 98] 4
(3–5)
3 · 02 [2
Use of insulin pump, n (%) 23 (1 · 8) 1
Use of ultra-rapid insulin analogs, n (%) 627 (52 · 5) 36
Use of basal insulin analogs n (%) 281 (21 · 5) 15
SMBG = self- monitoring of blood glucose. *Data presented as mean [95%CI] and mdeterminants of the costs were the presence of micro-
vascular diabetes-related complications (B −603 · 00, SE
64 · 36; β -0 · 165; p < 0 · 001), economic status (B −202 ·
57, SE 27 · 72; β -0 · 129; p < 0 · 001), and being from
the southeast region (B 197 · 95, SE 52 · 77; β 0 · 066;
p < 0 · 001). This model explained only 5 · 4% of the varia-
bility of the costs (R2 = 0 · 054).
Discussion
Brazil is a large country with a great cultural, socioeco-
nomic and demographic diversity. As previously demon-
strated [7], these diversities are also extrapolated to the
type of treatment and clinical care of T1D patients in
our country. From the present data we can see that
the direct medical costs of T1D also follow this same
pattern.
The first interesting issue raised by the present study
is the existence of two extremes in Brazil regarding
the characteristics, the care of patients with T1D and
the costs of the disease: the southeast and the north/
northeast regions. In the southeast region, the average
per capita costs of T1D was 28% and 17% higher than in
the north/northeast and in the south regions, respectively,
although not different from mid-west. In fact, being from
the Southeast region was independently associated with
higher medical costs. This finding could be explained by
the different pattern of treatment offered to patients living
and receiving treatment in each region which is reflected
in the costs. For example, a smaller proportion of patients
in the north/northeast region performed SMBG and when
performed, it was in a lower daily frequency. Moreover,ographic regions of Brazil
South North/Northeast Mid-West p-value
92 · 7 77 · 2 95 · 1 <0 · 001
· 91–3 · 13] 3
(2–4)
2 · 93 [2 · 76–3 · 10] 2
(2–3)
3 · 19 [3 · 00–3 · 37] 3
(2–4)
<0 · 001
0 (1 · 4) 2 (0 · 2) 3 (1 · 5) 0 · 009
4 (52 · 4) 122 (16 · 8) 98 (52 · 7) <0 · 001
6 (21 · 5) 108 (11 · 5) 73 (35 · 6) <0 · 001
edian (interquartile interval).
Table 4 Clinical and demographic differences among the geographic regions of Brazil
Southeast South North/Northeast Midwest P value
Gender (female), (%) 58 · 5 56 · 3 53 · 1 57 · 6 0 · 087
Ethnicity (Caucasian), (%) 58 · 7 87 · 3 34 · 6 46 · 3 <0 · 001
Age (y)* 22 · 0 ± 12 · 5 23 · 4 ± 12 · 3 20 · 9 ± 9 · 9 21 · 8 ± 11 · 9 0 · 017
Duration of diabetes (y)** 11 · 2 ± 8 · 8 11 · 4 ± 8 · 3 8 · 5 ± 6 · 4 9 · 4 ± 7 · 5 <0 · 001
Level of care*** (tertiary), (%) 93 · 1 94 · 2 34 · 9 24 · 9 <0 · 001
Low or very-low economic status (%)**** 66 · 1 58 · 1 86 · 1 58 · 2 <0 · 001
Prevalence of microvascular complications (%) 22 · 0 23 · 8 14 · 5 18 · 5 0 · 001
Presence of macrovascular complications (%) 5 · 1 3 · 2 2 · 5 2 · 9 0 · 004
SE = Southeast; N/NE = North/Northeast; MW =Midwest.
*p = 0 · 006 (SE vs South), p = 0 · 003 (South vs N/NE).
**p <0 · 001 (SE vs N/NE), p = 0 · 006 (SE vs MW), p <0 · 001 (South vs N/NE), p = 0 · 001 (South vs MW).
***p <0 · 001 (SE vs N/NE), p <0 · 001 (SE vs MW), p <0 · 001 (South vs N/NE), p <0 · 001 (South vs MW), p = 0 · 007 (N/NE vs MW).
****p <0 · 001 (N/NE vs MW), p = 0 · 042 (SE vs MW),p <0 · 001 (SE vs N/NE), p <0 · 001 (SE vs South), p = 0 · 02 (South vs MW), p <0 · 001 (N/NE vs South).
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human regular or NPH insulins. However, we also ob-
served that most patients in north/northeast belong to
low or very low socioeconomic status and are seen mostly
in secondary centers.
Another determinant of the costs of T1D in our study
was the socioeconomic status. What must be investi-
gated is 'how far it, which also reflects the educational
level in the ABEP classification, interferes with the
costs’? Intuitively, we can consider that both the patient
and the healthcare team can act to determine this differ-
ence. In the daily clinical practice physicians know that
the complexity of the treatment offered to the patients
should correspond to their acceptance and ability to
follow the recommendations adequately. Otherwise, it
would result in poor compliance and any proposed treat-
ment strategy would be inefficient. This means that we
are increasingly individualizing treatment in diabetes
and this has already reflected in the most recent guide-
lines recommendations for type 2 diabetes (T2D) treat-
ment [10]. These recommendations consider the patients’
motivation, adherence, and self-care capacities as well as
the resources and support system, as important factors in
choosing the best treatment for a particular patient. On
the other hand, patients with a higher education or even
cognitive level could act more positively in finding the best
available treatment options for him, many of which, are
more expensive. This is particularly important in manyTable 5 Per capita expenditure on public health services and
National Health Ministry of Brazil
Per capita expenditure
(US$/% Total)
2008 2009
North/Northeast 237 · 20 (21 · 8%) 256 · 89 (22 · 0%)
Southeast 306 · 17 (28 · 2%) 331 · 73 (28 · 5%)
South 257 · 89 (23 · 7%) 279 · 12 (23 · 9%)
Midwest 285 · 15 (26 · 3%) 297 · 86 (25 · 6%)cities in Brazil where the public health care system do not
provide insulin analogs and the supplies for SMBG in a
regular basis.
Other determinant of higher costs in T1D is the pre-
sence of chronic diabetes-related microvascular com-
plications. In epidemiological studies, it is important to
consider that the prevalence of chronic complications is
proportional to the frequency of screening and the sur-
vival to acute complications of the disease. Patients from
north/northeast presented lower prevalence of complica-
tions, which could reflect a survival bias. Intervention
studies, such as the Diabetes Control and Complications
Trial (DCCT), have shown that intensive treatment dur-
ing the early stages of T1D reduces the risk of future
microvascular complications [11]. Information derived
from clinical and economic trials can guide economic
policy decisions that aim to reduce direct costs by reallo-
cating resources toward preventing acute and chronic
diabetes-related complications. Increased costs due to
the presence of chronic diabetes-related complications
may have a future impact on health economics because
chronic complications become more prevalent as the
disease progresses.
The impact of T1D alone on the total investment in
the public health care system by the three spheres of
government, Federal, State and Municipal is unknown.
According to data from the National Health Ministry of
Brazil we have observed an increase in global healthactions for each geographic region according to the
2010 3-year mean Individual cost of T1D/
Per capita expenditure
282 · 23 (21 · 7%) 258 · 77 (21 · 8%) 4 · 44
373 · 87 (28 · 7%) 337 · 26 (28 · 5%) 4 · 35
321 · 06 (24 · 7%) 286 · 02 (24 · 2%) 4 · 38
323 · 52 (24 · 9%) 302 · 18 (25 · 5%) 4 · 62
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the country, which is determined by law. The per capita
expenditure is higher in the southeast and lowest in the
north/northeast regions (Table 5), consistent with the
trend of the per capita costs of T1D. However, patients
with T1D cost about 4 times the per capita expenditure
on public health services and actions by the Ministry of
Health in all regions. The fixed offer and the variable de-
mand could explain these similar relations despite the
differences in regional costs. Thus, it is likely that the
health investment cap would be a limiting factor in
the per capita costs of T1D.
Although the study design does not allow a complete
evaluation of the clinical and economic consequences of
the treatment of T1D in Brazil, we suspect that other
factors besides the economic status may interfere in clini-
cal outcomes and in meeting the recommended thera-
peutic goals. For instance, the southeast and mid-west
regions, despite having a 22% and 28% higher T1D per
capita costs, respectively, a greater frequency of SMBG
and proportion of insulin analogues use than the north/
northeast region, presented a similar low prevalence of pa-
tients within the recommended HbA1c targets [7].
Some study limitations must be addressed. The study
sample included only patients attended at public centers
on secondary or tertiary levels in urban areas. However,
according to the structure of care established by the
NBHCS, the vast majority of patients with T1D are
treated in these centers. Also, the collection of data may
have led to collection bias.
The present data reinforce the regional differences in
the health care provided to patients with T1D in specia-
lized public centers in Brazil, as well as the regional dif-
ferences in the socioeconomic and demographic profile
of the population. Both factors have directly influenced
the costs of T1D in Brazilian regions and should be con-
sidered for discussing future health policies.
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